APO Research
Talk to an analyst

APO RESEARCH · REPORT

Microbiome Therapeutics

The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.

An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

Selected research

Industry Research

Microbiome Therapeutics Industry Research Report 2026

2 January 2026144 pages

Choose your research edition.

Industry ResearchMicrobiome Therapeutics Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Microbiome Therapeutics Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Microbiome Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Microbiome Therapeutics Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Microbiome Therapeutics Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.

An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

Read the full market overview

The Application of Microbiome Therapeutics includes CDI, IBD, Orphan Drug, Immuno-oncology and Others, and the proportion of R&D Investmen for CDI is about 52%.

For Microbiome Therapeutics Pipeline Product, SER-109, ABI-H0731, ribaxamase, SYN-010 have the most investment in research, there are in Phase 3, PHASE 1b and Phase 2.

North American is the largest market, It occupy nearly 37% market share. Following North American, Europe is the second largest market with the consumption market share of 30%.

Market competition is not intense. Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon and PureTech are the leading Developers in the industry, with about 60% market shares.

Report Scope

This report quantifies the global Microbiome Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Microbiome Therapeutics.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Microbiome Therapeutics Market by Company

Seres Therapeutics

Assembly Biosciences

Synthetic Biologics

Interxon

PureTech

Synlogic

Enterome BioScience

4D Pharma

Second Genome

AOBiome

C3 Jian

Rebiotix

MicroBiome Therapeutics LLC

Metabiomics

Ritter Pharmaceuticals

Symberix

OpenBiome

Azitra

Symbiotix Biotherapies

Osel

Metabogen

Microbiome Therapeutics Segment by Type

Upper GIT

Lower GIT

Microbiome Therapeutics Segment by Application

C. difficile Infection (CDI)

Inflammatory Bowel Disease (IBD)

Orphan Drug

Immuno-oncology

Others

Microbiome Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Microbiome Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Microbiome Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Microbiome Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Microbiome Therapeutics Revenue Market Share by Type (2021-2026) Table 7. Global Microbiome Therapeutics Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Microbiome Therapeutics Revenue Market Share by Type (2027-2032) Table 9. Global Microbiome Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Microbiome Therapeutics Revenue Market Share by Application (2021-2026) Table 11. Global Microbiome Therapeutics Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Microbiome Therapeutics Revenue Market Share by Application (2027-2032) Table 13. Global Microbiome Therapeutics Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Microbiome Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Microbiome Therapeutics Market Share by Region (2021-2026) Table 16. Global Microbiome Therapeutics Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Microbiome Therapeutics Market Share by Region (2027-2032) Table 18. Microbiome Therapeutics Industry Trends Table 19. Microbiome Therapeutics Industry Drivers Table 20. Microbiome Therapeutics Industry Opportunities and Challenges Table 21. Microbiome Therapeutics Market Restraints Table 22. Global Top Microbiome Therapeutics Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Microbiome Therapeutics Revenue Market Share by Players (2021-2026) Table 24. Global Microbiome Therapeutics Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Microbiome Therapeutics, Headquarters and Area Served Table 26. Global Microbiome Therapeutics Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Microbiome Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Microbiome Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Microbiome Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Microbiome Therapeutics Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Microbiome Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Microbiome Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Microbiome Therapeutics Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Microbiome Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Microbiome Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Microbiome Therapeutics Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Microbiome Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Microbiome Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Microbiome Therapeutics Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Microbiome Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Microbiome Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Microbiome Therapeutics Market Size by Country (2027-2032) & (US$ Million) Table 45. Seres Therapeutics Company Information Table 46. Seres Therapeutics Business Overview Table 47. Seres Therapeutics Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 48. Seres Therapeutics Microbiome Therapeutics Product Portfolio Table 49. Seres Therapeutics Recent Developments Table 50. Assembly Biosciences Company Information Table 51. Assembly Biosciences Business Overview Table 52. Assembly Biosciences Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 53. Assembly Biosciences Microbiome Therapeutics Product Portfolio Table 54. Assembly Biosciences Recent Developments Table 55. Synthetic Biologics Company Information Table 56. Synthetic Biologics Business Overview Table 57. Synthetic Biologics Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 58. Synthetic Biologics Microbiome Therapeutics Product Portfolio Table 59. Synthetic Biologics Recent Developments Table 60. Interxon Company Information Table 61. Interxon Business Overview Table 62. Interxon Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 63. Interxon Microbiome Therapeutics Product Portfolio Table 64. Interxon Recent Developments Table 65. PureTech Company Information Table 66. PureTech Business Overview Table 67. PureTech Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 68. PureTech Microbiome Therapeutics Product Portfolio Table 69. PureTech Recent Developments Table 70. Synlogic Company Information Table 71. Synlogic Business Overview Table 72. Synlogic Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 73. Synlogic Microbiome Therapeutics Product Portfolio Table 74. Synlogic Recent Developments Table 75. Enterome BioScience Company Information Table 76. Enterome BioScience Business Overview Table 77. Enterome BioScience Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 78. Enterome BioScience Microbiome Therapeutics Product Portfolio Table 79. Enterome BioScience Recent Developments Table 80. 4D Pharma Company Information Table 81. 4D Pharma Business Overview Table 82. 4D Pharma Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 83. 4D Pharma Microbiome Therapeutics Product Portfolio Table 84. 4D Pharma Recent Developments Table 85. Second Genome Company Information Table 86. Second Genome Business Overview Table 87. Second Genome Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 88. Second Genome Microbiome Therapeutics Product Portfolio Table 89. Second Genome Recent Developments Table 90. AOBiome Company Information Table 91. AOBiome Business Overview Table 92. AOBiome Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 93. AOBiome Microbiome Therapeutics Product Portfolio Table 94. AOBiome Recent Developments Table 95. C3 Jian Company Information Table 96. C3 Jian Business Overview Table 97. C3 Jian Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 98. C3 Jian Microbiome Therapeutics Product Portfolio Table 99. C3 Jian Recent Developments Table 100. Rebiotix Company Information Table 101. Rebiotix Business Overview Table 102. Rebiotix Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 103. Rebiotix Microbiome Therapeutics Product Portfolio Table 104. Rebiotix Recent Developments Table 105. MicroBiome Therapeutics LLC Company Information Table 106. MicroBiome Therapeutics LLC Business Overview Table 107. MicroBiome Therapeutics LLC Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 108. MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio Table 109. MicroBiome Therapeutics LLC Recent Developments Table 110. Metabiomics Company Information Table 111. Metabiomics Business Overview Table 112. Metabiomics Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 113. Metabiomics Microbiome Therapeutics Product Portfolio Table 114. Metabiomics Recent Developments Table 115. Ritter Pharmaceuticals Company Information Table 116. Ritter Pharmaceuticals Business Overview Table 117. Ritter Pharmaceuticals Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 118. Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio Table 119. Ritter Pharmaceuticals Recent Developments Table 120. Symberix Company Information Table 121. Symberix Business Overview Table 122. Symberix Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 123. Symberix Microbiome Therapeutics Product Portfolio Table 124. Symberix Recent Developments Table 125. OpenBiome Company Information Table 126. OpenBiome Business Overview Table 127. OpenBiome Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 128. OpenBiome Microbiome Therapeutics Product Portfolio Table 129. OpenBiome Recent Developments Table 130. Azitra Company Information Table 131. Azitra Business Overview Table 132. Azitra Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 133. Azitra Microbiome Therapeutics Product Portfolio Table 134. Azitra Recent Developments Table 135. Symbiotix Biotherapies Company Information Table 136. Symbiotix Biotherapies Business Overview Table 137. Symbiotix Biotherapies Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 138. Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio Table 139. Symbiotix Biotherapies Recent Developments Table 140. Osel Company Information Table 141. Osel Business Overview Table 142. Osel Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 143. Osel Microbiome Therapeutics Product Portfolio Table 144. Osel Recent Developments Table 145. Metabogen Company Information Table 146. Metabogen Business Overview Table 147. Metabogen Revenue in Microbiome Therapeutics Business (2021-2026) & (US$ Million) Table 148. Metabogen Microbiome Therapeutics Product Portfolio Table 149. Metabogen Recent Developments Table 150. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Microbiome Therapeutics Product Image Figure 5. Global Microbiome Therapeutics Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Microbiome Therapeutics Market Share by Type: 2025 VS 2032 Figure 7. Upper GIT Product Figure 8. Lower GIT Product Figure 9. Global Microbiome Therapeutics Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Microbiome Therapeutics Market Share by Application: 2025 VS 2032 Figure 11. C. difficile Infection (CDI) Product Figure 12. Inflammatory Bowel Disease (IBD) Product Figure 13. Orphan Drug Product Figure 14. Immuno-oncology Product Figure 15. Others Product Figure 16. Global Microbiome Therapeutics Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 17. Global Microbiome Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Microbiome Therapeutics Market Share by Region: 2025 VS 2032 Figure 19. Global Microbiome Therapeutics Market Share by Players in 2025 Figure 20. Global Microbiome Therapeutics Manufacturers Established Date Figure 21. Global Top 5 and 10 Microbiome Therapeutics Players Market Share by Revenue in 2025 Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. North America Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Microbiome Therapeutics Market Share by Country (2021-2032) Figure 25. United States Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 26. Canada Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Mexico Microbiome Therapeutics Market Share by Country (2021-2032) Figure 28. Europe Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Microbiome Therapeutics Market Share by Country (2021-2032) Figure 30. Germany Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. France Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. U.K. Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Italy Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Spain Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Russia Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Netherlands Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Nordic Countries Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Microbiome Therapeutics Market Share by Country (2021-2032) Figure 40. China Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. Japan Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. South Korea Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. India Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. India Microbiome Therapeutics Market Share by Country (2021-2032) Figure 45. Australia Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. China Taiwan Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. Southeast Asia Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. South America Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. South America Microbiome Therapeutics Market Share by Country (2021-2032) Figure 50. Brazil Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Argentina Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Chile Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Colombia Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. Peru Microbiome Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 55. Seres Therapeutics Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 56. Assembly Biosciences Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 57. Synthetic Biologics Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 58. Interxon Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 59. PureTech Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 60. Synlogic Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 61. Enterome BioScience Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 62. 4D Pharma Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 63. Second Genome Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 64. AOBiome Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 65. C3 Jian Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 66. Rebiotix Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 67. MicroBiome Therapeutics LLC Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 68. Metabiomics Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 69. Ritter Pharmaceuticals Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 70. Symberix Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 71. OpenBiome Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 72. Azitra Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 73. Symbiotix Biotherapies Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 74. Osel Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026) Figure 75. Metabogen Revenue Growth Rate in Microbiome Therapeutics Business (2021-2026)

Scope & coverage.

Types
  • Upper GIT
  • Lower GIT
Applications
  • C. difficile Infection (CDI)
  • Inflammatory Bowel Disease (IBD)
  • Orphan Drug
  • Immuno-oncology
  • Others
Companies covered
  • Seres Therapeutics
  • Assembly Biosciences
  • Synthetic Biologics
  • Interxon
  • PureTech
  • Synlogic
  • Enterome BioScience
  • 4D Pharma
  • Second Genome
  • AOBiome
  • C3 Jian
  • Rebiotix
  • MicroBiome Therapeutics LLC
  • Metabiomics
  • Ritter Pharmaceuticals
  • Symberix
  • OpenBiome
  • Azitra
  • Symbiotix Biotherapies
  • Osel
  • Metabogen

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Microbiome Therapeutics by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Upper GIT
  5. 2.2.3 Lower GIT
  6. 2.3 Microbiome Therapeutics by Application
  7. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  8. 2.3.2 C. difficile Infection (CDI)
  9. 2.3.3 Inflammatory Bowel Disease (IBD)
  10. 2.3.4 Orphan Drug
  11. 2.3.5 Immuno-oncology
  12. 2.3.6 Others
  13. 2.4 Assumptions and Limitations
3 Microbiome Therapeutics Breakdown Data by Type
  1. 3.1 Global Microbiome Therapeutics Historic Market Size by Type (2021-2026)
  2. 3.2 Global Microbiome Therapeutics Forecasted Market Size by Type (2027-2032)
4 Microbiome Therapeutics Breakdown Data by Application
  1. 4.1 Global Microbiome Therapeutics Historic Market Size by Application (2021-2026)
  2. 4.2 Global Microbiome Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Microbiome Therapeutics Market Perspective (2021-2032)
  2. 5.2 Global Microbiome Therapeutics Growth Trends by Region
  3. 5.2.1 Global Microbiome Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Microbiome Therapeutics Historic Market Size by Region (2021-2026)
  5. 5.2.3 Microbiome Therapeutics Forecasted Market Size by Region (2027-2032)
  6. 5.3 Microbiome Therapeutics Market Dynamics
  7. 5.3.1 Microbiome Therapeutics Industry Trends
  8. 5.3.2 Microbiome Therapeutics Market Drivers
  9. 5.3.3 Microbiome Therapeutics Market Challenges
  10. 5.3.4 Microbiome Therapeutics Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Microbiome Therapeutics Players by Revenue
  2. 6.1.1 Global Top Microbiome Therapeutics Players by Revenue (2021-2026)
  3. 6.1.2 Global Microbiome Therapeutics Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Microbiome Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Microbiome Therapeutics Head Office and Area Served
  6. 6.4 Global Microbiome Therapeutics Players, Product Type & Application
  7. 6.5 Global Microbiome Therapeutics Manufacturers Established Date
  8. 6.6 Global Microbiome Therapeutics Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Microbiome Therapeutics Market Size (2021-2032)
  2. 7.2 North America Microbiome Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Microbiome Therapeutics Market Size by Country (2021-2026)
  4. 7.4 North America Microbiome Therapeutics Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Microbiome Therapeutics Market Size (2021-2032)
  2. 8.2 Europe Microbiome Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Microbiome Therapeutics Market Size by Country (2021-2026)
  4. 8.4 Europe Microbiome Therapeutics Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Microbiome Therapeutics Market Size (2021-2032)
  2. 9.2 Asia-Pacific Microbiome Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Microbiome Therapeutics Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Microbiome Therapeutics Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Microbiome Therapeutics Market Size (2021-2032)
  2. 10.2 South America Microbiome Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Microbiome Therapeutics Market Size by Country (2021-2026)
  4. 10.4 South America Microbiome Therapeutics Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Microbiome Therapeutics Market Size (2021-2032)
  2. 11.2 Middle East & Africa Microbiome Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Microbiome Therapeutics Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Microbiome Therapeutics Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Seres Therapeutics
  2. 12.1.1 Seres Therapeutics Company Information
  3. 12.1.2 Seres Therapeutics Business Overview
  4. 12.1.3 Seres Therapeutics Revenue in Microbiome Therapeutics Business (2021-2026)
  5. 12.1.4 Seres Therapeutics Microbiome Therapeutics Product Portfolio
  6. 12.1.5 Seres Therapeutics Recent Developments
  7. 12.2 Assembly Biosciences
  8. 12.2.1 Assembly Biosciences Company Information
  9. 12.2.2 Assembly Biosciences Business Overview
  10. 12.2.3 Assembly Biosciences Revenue in Microbiome Therapeutics Business (2021-2026)
  11. 12.2.4 Assembly Biosciences Microbiome Therapeutics Product Portfolio
  12. 12.2.5 Assembly Biosciences Recent Developments
  13. 12.3 Synthetic Biologics
  14. 12.3.1 Synthetic Biologics Company Information
  15. 12.3.2 Synthetic Biologics Business Overview
  16. 12.3.3 Synthetic Biologics Revenue in Microbiome Therapeutics Business (2021-2026)
  17. 12.3.4 Synthetic Biologics Microbiome Therapeutics Product Portfolio
  18. 12.3.5 Synthetic Biologics Recent Developments
  19. 12.4 Interxon
  20. 12.4.1 Interxon Company Information
  21. 12.4.2 Interxon Business Overview
  22. 12.4.3 Interxon Revenue in Microbiome Therapeutics Business (2021-2026)
  23. 12.4.4 Interxon Microbiome Therapeutics Product Portfolio
  24. 12.4.5 Interxon Recent Developments
  25. 12.5 PureTech
  26. 12.5.1 PureTech Company Information
  27. 12.5.2 PureTech Business Overview
  28. 12.5.3 PureTech Revenue in Microbiome Therapeutics Business (2021-2026)
  29. 12.5.4 PureTech Microbiome Therapeutics Product Portfolio
  30. 12.5.5 PureTech Recent Developments
  31. 12.6 Synlogic
  32. 12.6.1 Synlogic Company Information
  33. 12.6.2 Synlogic Business Overview
  34. 12.6.3 Synlogic Revenue in Microbiome Therapeutics Business (2021-2026)
  35. 12.6.4 Synlogic Microbiome Therapeutics Product Portfolio
  36. 12.6.5 Synlogic Recent Developments
  37. 12.7 Enterome BioScience
  38. 12.7.1 Enterome BioScience Company Information
  39. 12.7.2 Enterome BioScience Business Overview
  40. 12.7.3 Enterome BioScience Revenue in Microbiome Therapeutics Business (2021-2026)
  41. 12.7.4 Enterome BioScience Microbiome Therapeutics Product Portfolio
  42. 12.7.5 Enterome BioScience Recent Developments
  43. 12.8 4D Pharma
  44. 12.8.1 4D Pharma Company Information
  45. 12.8.2 4D Pharma Business Overview
  46. 12.8.3 4D Pharma Revenue in Microbiome Therapeutics Business (2021-2026)
  47. 12.8.4 4D Pharma Microbiome Therapeutics Product Portfolio
  48. 12.8.5 4D Pharma Recent Developments
  49. 12.9 Second Genome
  50. 12.9.1 Second Genome Company Information
  51. 12.9.2 Second Genome Business Overview
  52. 12.9.3 Second Genome Revenue in Microbiome Therapeutics Business (2021-2026)
  53. 12.9.4 Second Genome Microbiome Therapeutics Product Portfolio
  54. 12.9.5 Second Genome Recent Developments
  55. 12.10 AOBiome
  56. 12.10.1 AOBiome Company Information
  57. 12.10.2 AOBiome Business Overview
  58. 12.10.3 AOBiome Revenue in Microbiome Therapeutics Business (2021-2026)
  59. 12.10.4 AOBiome Microbiome Therapeutics Product Portfolio
  60. 12.10.5 AOBiome Recent Developments
  61. 12.11 C3 Jian
  62. 12.11.1 C3 Jian Company Information
  63. 12.11.2 C3 Jian Business Overview
  64. 12.11.3 C3 Jian Revenue in Microbiome Therapeutics Business (2021-2026)
  65. 12.11.4 C3 Jian Microbiome Therapeutics Product Portfolio
  66. 12.11.5 C3 Jian Recent Developments
  67. 12.12 Rebiotix
  68. 12.12.1 Rebiotix Company Information
  69. 12.12.2 Rebiotix Business Overview
  70. 12.12.3 Rebiotix Revenue in Microbiome Therapeutics Business (2021-2026)
  71. 12.12.4 Rebiotix Microbiome Therapeutics Product Portfolio
  72. 12.12.5 Rebiotix Recent Developments
  73. 12.13 MicroBiome Therapeutics LLC
  74. 12.13.1 MicroBiome Therapeutics LLC Company Information
  75. 12.13.2 MicroBiome Therapeutics LLC Business Overview
  76. 12.13.3 MicroBiome Therapeutics LLC Revenue in Microbiome Therapeutics Business (2021-2026)
  77. 12.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio
  78. 12.13.5 MicroBiome Therapeutics LLC Recent Developments
  79. 12.14 Metabiomics
  80. 12.14.1 Metabiomics Company Information
  81. 12.14.2 Metabiomics Business Overview
  82. 12.14.3 Metabiomics Revenue in Microbiome Therapeutics Business (2021-2026)
  83. 12.14.4 Metabiomics Microbiome Therapeutics Product Portfolio
  84. 12.14.5 Metabiomics Recent Developments
  85. 12.15 Ritter Pharmaceuticals
  86. 12.15.1 Ritter Pharmaceuticals Company Information
  87. 12.15.2 Ritter Pharmaceuticals Business Overview
  88. 12.15.3 Ritter Pharmaceuticals Revenue in Microbiome Therapeutics Business (2021-2026)
  89. 12.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio
  90. 12.15.5 Ritter Pharmaceuticals Recent Developments
  91. 12.16 Symberix
  92. 12.16.1 Symberix Company Information
  93. 12.16.2 Symberix Business Overview
  94. 12.16.3 Symberix Revenue in Microbiome Therapeutics Business (2021-2026)
  95. 12.16.4 Symberix Microbiome Therapeutics Product Portfolio
  96. 12.16.5 Symberix Recent Developments
  97. 12.17 OpenBiome
  98. 12.17.1 OpenBiome Company Information
  99. 12.17.2 OpenBiome Business Overview
  100. 12.17.3 OpenBiome Revenue in Microbiome Therapeutics Business (2021-2026)
  101. 12.17.4 OpenBiome Microbiome Therapeutics Product Portfolio
  102. 12.17.5 OpenBiome Recent Developments
  103. 12.18 Azitra
  104. 12.18.1 Azitra Company Information
  105. 12.18.2 Azitra Business Overview
  106. 12.18.3 Azitra Revenue in Microbiome Therapeutics Business (2021-2026)
  107. 12.18.4 Azitra Microbiome Therapeutics Product Portfolio
  108. 12.18.5 Azitra Recent Developments
  109. 12.19 Symbiotix Biotherapies
  110. 12.19.1 Symbiotix Biotherapies Company Information
  111. 12.19.2 Symbiotix Biotherapies Business Overview
  112. 12.19.3 Symbiotix Biotherapies Revenue in Microbiome Therapeutics Business (2021-2026)
  113. 12.19.4 Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio
  114. 12.19.5 Symbiotix Biotherapies Recent Developments
  115. 12.20 Osel
  116. 12.20.1 Osel Company Information
  117. 12.20.2 Osel Business Overview
  118. 12.20.3 Osel Revenue in Microbiome Therapeutics Business (2021-2026)
  119. 12.20.4 Osel Microbiome Therapeutics Product Portfolio
  120. 12.20.5 Osel Recent Developments
  121. 12.21 Metabogen
  122. 12.21.1 Metabogen Company Information
  123. 12.21.2 Metabogen Business Overview
  124. 12.21.3 Metabogen Revenue in Microbiome Therapeutics Business (2021-2026)
  125. 12.21.4 Metabogen Microbiome Therapeutics Product Portfolio
  126. 12.21.5 Metabogen Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst